Sherbrooke’s Immune Biosolutions Says Their Drug Neutralizes COVID-19

by

Inhaled immunotherapy is in phase 1 and 2 clinical trials.

Publication date:

January 11, 2022 • 5 minutes ago • 1 minute read

An undated scanning electron microscope image shows SARS-CoV-2 (round golden objects), also known as novel coronavirus, the virus that causes COVID-19, emerging from the surface of cells grown in the laboratory and isolated from a patient in the USA
An undated scanning electron microscope image shows SARS-CoV-2 (round golden objects), also known as novel coronavirus, the virus that causes COVID-19, emerging from the surface of cells grown in the laboratory and isolated from a patient in the USA Photo by NIAID /via REUTERS

SHERBROOKE: A Sherbrooke-based company, Immune Biosolutions, says it has developed a biological drug candidate that is “capable of neutralizing SARS-CoV-2 (COVID-19) and all of its current variants of concern that have arisen during the pandemic, including the latest variant of Omicron ”.

Reference-montrealgazette.com

Leave a Comment